Background/ Aim MicroRNAs (miRNAs) are known up-to-date candidate biomarkers for several diseases. In addition obtaining miRNA from different body fluids such as serum, plasma, saliva, and urine is relatively easy to handle. Herein we aimed to detect miRNAs as biomarkers for early stage prostate cancer (PC). For this purpose, we used urine and serum samples to detect any significant differences in miRNA profiles between patients and healthy controls.
  Total ribonucleic acid (RNA) in urine and serum samples were isolated from eight untreated PC patients and thirty healthy individuals were screened for miRNA profile and candidate miRNAs were validated. Whole urinary and serum miRNA profile was analyzed using Affymetrix GeneChip miRNA 4.0 Arrays. Candidate miRNAs were investigated by stem-loop reverse transcription - polymerase chain reaction.
 
  According to our results, when analyzed urinary samples of PC patients 49 miRNAs were detected up-regulated and 14 miRNAs were found down-regulated when compared with heC.
  Magnetic resonance (MR) images, signal intensity ratios calculated using region of interests (ROI) in T2W images by proportioning the dominant myoma to iliac muscle can aid patient selection and, thus, in achieving better outcomes with the uterine artery embolization (UAE) procedure.
 
  The present study investigates the association between the success of UAE treatment with signal intensity (SI) ratio of the dominant myoma to the iliac muscle in MR imaging performed prior to the procedure.
 
  This is a retrospective study and included 30 patients who admitted to our clinic between February 2017 and July 2019 due to symptoms associated with myoma and who underwent MR imaging before and after UAE treatment. All patients, MR images obtained before UAE treatment and at the 12th month after the procedure were evaluated. In MRI, SI values were calculated by proportioning the dominant myoma to the iliac muscle using circular ROI in T1 Weighted (W), T2W, and post-contrast T1W images. In the present study, 50% or more volumetric regression of the myoma with infarction of fibroids (loss of enhancement) at the 12-month follow-up MRI after the procedure was considered a successful procedure.
 
  Myoma volumes calculated in MR images showed significant differences between the MRI performed before UAE procedure and the MRI performed at the 12th month after the procedure (p<0.0001). SI ratio calculated from pre-procedure T2W MR images was found to be a significant determinant of 50% or more volumetric regression in the myoma after UAE procedure (p=0.017), T1W, post-contrast T1W images were not statistically significant (p=0.211).
 
  Our results indicate that SI ratio of the dominant myoma to the iliac muscle calculated using ROI in T2W images of MR studies performed before UAE procedure can predict the success of the procedure.
 Our results indicate that SI ratio of the dominant myoma to the iliac muscle calculated using ROI in T2W images of MR studies performed before UAE procedure can predict the success of the procedure.
  In this study, we aimed to compare the results of prone and Barts ?flank-free? modified supine percutaneous nephrolithotomy (PCNL) operations in our clinic.
 
  The data from patients that underwent Barts ?flank-free? modified supine PCNL (BS-PCNL) (n=52) between June 2018 and July 2020 and prone PCNL (P-PCNL) (n=286) between April 2014 and June 2018 were retrospectively evaluated. Of those 286 patients, 104 patients whose gender, age, body mass index, American Society of Anesthesiology score, stone localization, stone size, and hydronephrosis matched the BS-PCNL group in a 12 ratio were included in the study. The groups were compared in terms of intraoperative outcome, complication rates, and stone-free rates.
 
  The mean age of all patients (58 females, 98 males) included in the study was 41.8±15.2 years, and the mean body mass index (BMI) was 24.7±2.9 kg/m2.  https://www.selleckchem.com/products/sulfopin.html  The mean operation time was significantly shorter in the BS-PCNL group than in the P-PCNL group (80.2±15.1 min vs. 92.4±22.7 min and p=0.01). There was no significant difference between the two groups in terms of fluoroscopy time, intraoperative complications, postoperative complications, and stone-free rates.
 
  Our study shows that BS-PCNL is an effective and safe method that significantly reduces the operation time and should be considered as one of the primary treatment options for patients scheduled for PCNL.
 Our study shows that BS-PCNL is an effective and safe method that significantly reduces the operation time and should be considered as one of the primary treatment options for patients scheduled for PCNL.
  Numerous studies show that cancer risk is reduced by consumption of soy-based foods containing genistein, but its effects on the glycogen synthase kinase-3 pathway (GSK-3) in ovarian cancer is unknown. Therefore, we tested the properties of genistein on inflammatory biomarkers and GSK-3 signaling pathways in the ovaries of old laying hens with ovarian cancer.
 
  A total of 300 laying hens were distributed into 3 groups as follows group 1, animals fed a standard diet (comprising 22.39 mg of genistein/kg of diet); groups 2 and 3, animals fed a standard diet reconstituted with supplementation of 400 mg or 800 mg of genistein/kg of diet, respectively.
 
  Genistein modulated the inflammatory biomarkers by decreasing serum tumor necrosis factor-? (TNF-?), interleukin-6 (IL-6), interleukin-8 (IL-8), and vascular endothelial growth factor (VEGF) compared with control (P < 0.001). Moreover, genistein up-regulated insulin receptor substrate-1 (p-IRS-1) and protein kinase B (p-AKT), but down-regulated GSK-3? and ß after treatment. Genistein acts in a dose-dependent manner.
 
  Genistein exhibited an anticancer effect by reducing pro-inflammatory biomarkers levels and inhibiting GSK-3 expression in the ovaries of old laying hens. Genistein is a potential candidate in the chemoprevention and/or treatment of ovarian cancer.
 Genistein exhibited an anticancer effect by reducing pro-inflammatory biomarkers levels and inhibiting GSK-3 expression in the ovaries of old laying hens. Genistein is a potential candidate in the chemoprevention and/or treatment of ovarian cancer.